Kiniksa Pharmaceuticals International, plc

NasdaqGS:KNSA Stock Report

Market Cap: US$1.7b

Kiniksa Pharmaceuticals International Valuation

Is KNSA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KNSA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$58.66
Fair Value
59.4% undervalued intrinsic discount
7
Number of Analysts

Below Fair Value: KNSA ($23.81) is trading below our estimate of fair value ($58.66)

Significantly Below Fair Value: KNSA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KNSA?

Key metric: As KNSA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for KNSA. This is calculated by dividing KNSA's market cap by their current revenue.
What is KNSA's PS Ratio?
PS Ratio4.1x
SalesUS$423.24m
Market CapUS$1.68b

Price to Sales Ratio vs Peers

How does KNSA's PS Ratio compare to its peers?

The above table shows the PS ratio for KNSA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average22.8x
MNKD MannKind
5.6x13.1%US$1.6b
IMCR Immunocore Holdings
4.9x18.1%US$1.4b
BEAM Beam Therapeutics
29.2x37.1%US$1.9b
AGIO Agios Pharmaceuticals
51.3x47.9%US$1.8b
KNSA Kiniksa Pharmaceuticals International
4.1x16.0%US$1.7b

Price-To-Sales vs Peers: KNSA is good value based on its Price-To-Sales Ratio (4.1x) compared to the peer average (22.8x).

Price to Sales Ratio vs Industry

How does KNSA's PS Ratio compare vs other companies in the US Biotechs Industry?

141 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.1x-0.1%US$20.70b
MRNA Moderna
3.9x16.9%US$12.88b
INCY Incyte
2.8x3.4%US$11.68b
EXAS Exact Sciences
3x9.5%US$8.49b
KNSA 4.1xIndustry Avg. 9.8xNo. of Companies141PS01632486480+
141 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: KNSA is good value based on its Price-To-Sales Ratio (4.1x) compared to the US Biotechs industry average (9.9x).

Price to Sales Ratio vs Fair Ratio

What is KNSA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KNSA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.1x
Fair PS Ratio4.2x

Price-To-Sales vs Fair Ratio: KNSA is good value based on its Price-To-Sales Ratio (4.1x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KNSA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$23.81
US$35.86
+50.6%
10.8%US$40.00US$30.00n/a7
Mar ’26US$20.28
US$35.17
+73.4%
10.7%US$40.00US$30.00n/a6
Feb ’26US$19.60
US$36.00
+83.7%
8.3%US$40.00US$32.00n/a6
Jan ’26US$19.78
US$36.00
+82.0%
8.3%US$40.00US$32.00n/a6
Dec ’25US$22.08
US$36.00
+63.0%
8.3%US$40.00US$32.00n/a6
Nov ’25US$22.48
US$35.83
+59.4%
7.8%US$40.00US$32.00n/a6
Oct ’25US$25.47
US$35.00
+37.4%
10.2%US$40.00US$30.00n/a6
Sep ’25US$26.74
US$32.83
+22.8%
10.0%US$38.00US$28.00n/a6
Aug ’25US$25.77
US$32.83
+27.4%
10.0%US$38.00US$28.00n/a6
Jul ’25US$18.00
US$30.67
+70.4%
6.1%US$34.00US$28.00n/a6
Jun ’25US$19.01
US$30.67
+61.3%
6.1%US$34.00US$28.00n/a6
May ’25US$19.40
US$30.00
+54.6%
4.2%US$32.00US$28.00n/a5
Apr ’25US$19.70
US$27.80
+41.1%
8.6%US$32.00US$25.00n/a5
Mar ’25US$21.74
US$27.40
+26.0%
10.2%US$32.00US$24.00US$20.285
Feb ’25US$18.21
US$27.40
+50.5%
10.2%US$32.00US$24.00US$19.605
Jan ’25US$17.54
US$26.20
+49.4%
13.1%US$32.00US$23.00US$19.785
Dec ’24US$16.81
US$26.20
+55.9%
13.1%US$32.00US$23.00US$22.085
Nov ’24US$15.14
US$26.40
+74.4%
12.4%US$32.00US$23.00US$22.485
Oct ’24US$17.37
US$25.40
+46.2%
16.4%US$32.00US$20.00US$25.475
Sep ’24US$17.76
US$25.40
+43.0%
16.4%US$32.00US$20.00US$26.745
Aug ’24US$18.90
US$24.60
+30.2%
19.2%US$32.00US$20.00US$25.775
Jul ’24US$14.08
US$21.80
+54.8%
15.5%US$28.00US$18.00US$18.005
Jun ’24US$14.16
US$21.80
+54.0%
15.5%US$28.00US$18.00US$19.015
May ’24US$10.98
US$21.60
+96.7%
15.9%US$28.00US$18.00US$19.405
Apr ’24US$10.76
US$21.60
+100.7%
15.9%US$28.00US$18.00US$19.705
Mar ’24US$12.57
US$21.00
+67.1%
19.0%US$28.00US$16.00US$21.745
Analyst Price Target
Consensus Narrative from 7 Analysts
US$35.86
Fair Value
33.6% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/20 03:50
End of Day Share Price 2025/03/20 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kiniksa Pharmaceuticals International, plc is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Geoff MeachamCitigroup Inc
Liisa BaykoEvercore ISI